0001437749-23-004378.txt : 20230223 0001437749-23-004378.hdr.sgml : 20230223 20230223155105 ACCESSION NUMBER: 0001437749-23-004378 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230223 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LEMAITRE VASCULAR INC CENTRAL INDEX KEY: 0001158895 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33092 FILM NUMBER: 23659429 BUSINESS ADDRESS: STREET 1: 63 SECOND AVENUE CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: 781-221-2266 MAIL ADDRESS: STREET 1: 63 SECOND AVENUE CITY: BURLINGTON STATE: MA ZIP: 01803 8-K 1 lmat20230223_8k.htm FORM 8-K lmat20230223_8k.htm
false 0001158895 0001158895 2023-02-23 2023-02-23
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  February 23, 2023
 
LeMaitre Vascular, Inc.
(Exact name of registrant as specified in its charter)
 
Commission File Number:  001-33092
 
Delaware
 
04-2825458
(State or other jurisdiction of
 
(IRS Employer
incorporation)
 
Identification No.)
 
63 Second Avenue
Burlington, MA 01803
(Address of principal executive offices, including zip code)
 
781-221-2266
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Exchange Act:
 
Title of each class
Trading symbol
Name of exchange on which registered
Common stock, $0.01 par value per share
LMAT 
The Nasdaq Global Market
 
Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
 
 
 
 
Item 2.02. Results of Operations and Financial Condition.
 
On February 23, 2023, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Report.
 
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
 
Disclaimer on Forward-Looking Statements
 
This current report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at http://www.lemaitre.com and on the SEC’s website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
 
 
Item 9.01. Financial Statements and Exhibits.
 
The following exhibits are furnished or filed as part of this Report, as applicable:
 
 
(d)
Exhibits.
 
     
Exhibit No.
  
Description
     
99.1
  
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
Signature(s)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
    
LeMaitre Vascular, Inc.
                 
                 
Date: February 23, 2023
 
 
 
By:
  
Joseph P. Pellegrino, Jr.
/s/ JOSEPH P. PELLEGRINO, JR.
               
Joseph P. Pellegrino, Jr.
Chief Financial Officer
 
 
 
 
Exhibit Index
     
Exhibit No.
  
       Description
     
99.1
  
       Press release issued by LeMaitre Vascular, Inc. on February 23, 2023.
104          Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 EX-99.1 2 ex_479795.htm EXHIBIT 99.1 ex_479795.htm

Exhibit 99.1

 

 

LeMaitre Q4 2022 Financial Results

 

BURLINGTON, MA, February 23, 2023 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2022 results, announced a $0.14/share quarterly dividend (+12%) and provided guidance.

 

Q4 2022 Financial Results

 

●         Sales $41.0mm, +4% (+8% organic) vs. Q4 2021

●         Op. income $7.0mm, -16%

●         Op. margin 17%

●         Net income $5.6mm, -9%

●         Earnings per diluted share $0.25, -9%

●         Cash and investments +$3.0mm to $82.7mm

 

Bovine patches (+11%), carotid shunts (+24%) and bovine grafts (+11%) drove sales growth in Q4 2022. Organic sales increased 22% in APAC, 9% in EMEA and 6% in the Americas. APAC and EMEA each reported record sales.

 

The gross margin decreased to 63.6% in Q4 2022 (vs. 65.7% in Q4 2021), with the strong dollar accounting for 150 basis points of this decline. 219 direct labor employees were on staff at year-end, up 54%.

 

Operating income declined 16% to $7.0mm in Q4 2022. Operating expenses grew 8%, driven by a 27% increase in sales representatives to 131.

 

George LeMaitre, Chairman and CEO, said “In Q4 we grew sales 8% organically and our guidance for Q1 is 11% on a reported basis and 13% organically. Our two key 2022 initiatives - the Burlington factory expansion and the rep surge - should drive improved top- and bottom-line results in 2023.” 

 

Business Outlook

 

 

 

Q1 2023 Guidance

 

 2023 Full Year Guidance

Sales

$42.6mm - $45.0mm

(Mid: $43.8mm, +11%, +13% Org.)

$174.3mm - $178.3mm

(Mid:$ 176.3mm, +9%, +9% Org.)

Gross Margin

 64.8% 65.4%

Op. Income

$6.0mm - $7.5mm

(Mid: $6.7mm, -15%)

$30.6mm - $33.3mm

(Mid $31.9mm, +19%, +7% Ex.Special)

EPS

$0.22 - $0.27

(Mid: $0.25, -10%)

$1.11 - $1.20

(Mid: $1.16, +24%, +8% Ex.Special)

 

Quarterly Dividend

 

On February 21, 2023, the Company's Board of Directors approved a quarterly dividend of $0.14/share of common stock. The dividend will be paid on March 23, 2023 to shareholders of record on March 9, 2023.

 

Share Repurchase Program

 

On February 21, 2023, the Company's Board of Directors authorized the repurchase of up to $25.0mm of the Company’s common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 21, 2024, unless extended by the Board.

 

Conference Call Reminder

 

Management will conduct a conference call at 5:00pm ET today. The conference call will be broadcast live over the Internet. Individuals interested in listening to the webcast can log on to the Company's website at www.lemaitre.com/investor. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at http://www.lemaitre.com/investor. For individuals unable to join the live conference call, a replay will be available on the Company's website.

 

A reconciliation of GAAP to non-GAAP results is included in the tables attached to this release.

 

 
 

 

About LeMaitre

 

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.

 

For more information about the Company, please visit http://www.lemaitre.com.

 

Use of Non-GAAP Financial Measures

 

LeMaitre management believes that in order to better understand the Company's short- and long-term financial trends, investors may wish to consider certain non-GAAP financial measures as a supplement to financial performance measures prepared in accordance with GAAP. Non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and do not have standardized meanings. These non-GAAP measures result from facts and circumstances that may vary in frequency and/or impact on continuing operations. Non-GAAP measures should be considered in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. In addition to the description provided below, reconciliation of GAAP to non-GAAP results is provided in the financial statement tables included in this press release.

 

In this press release, the Company has reported non-GAAP sales growth percentages after adjusting for the impact of foreign currency exchange, business development transactions, and/or other events, and have provided guidance for operating income and EPS excluding the special charge relating to the closure of our St. Etienne factory. The Company refers to the calculation of non-GAAP sales growth percentages as "organic." The Company analyzes non-GAAP sales on a constant currency basis, net of acquisitions and other non-recurring events, and the aforementioned non-GAAP profitability measures to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, and acquisitions, divestitures, product discontinuations, factory closures, and other strategic transactions are episodic in nature and are highly variable to the reported sales results, the Company believes that evaluating growth in sales on a constant currency basis net of such transactions provides an additional and meaningful assessment of sales to management. The Company believes that the presentation of guidance for operating income and EPS excluding special charge provides an alternative and meaningful view of the Company’s profitability excluding the impact of the closure of the Company’s St. Etienne, France factory, a non-recurring event.

 

Forward-Looking Statements

 

The Company's current financial results, as discussed in this release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results expected, including, but not limited to, the status of our global regulatory approvals and compliance with regulatory requirements to market and sell our products both in the U.S. and outside of the U.S.; the duration and severity of the impact of COVID-19 on the global economy, our customers, our suppliers and our company; the risk of significant fluctuations in our quarterly and annual results due to numerous factors; the risk that assumptions about the market for the Company’s products and the productivity of the Company’s direct sales force and distributors may not be correct; the risk that we may not be able to maintain our recent levels of profitability; the risk that the Company may not realize the anticipated benefits of its strategic activities; risks related to the integration of acquisition targets; the acceleration or deceleration of product growth rates; risks related to product demand and market acceptance of the Company’s products and pricing; the risk that a recall of our products could result in significant costs or negative publicity; the risk that the Company is not successful in transitioning to a direct-selling model in new territories and other risks and uncertainties included under the heading "Risk Factors" in our most recent Annual Report on Form 10-K, as updated by our subsequent filings with the SEC, which are all available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

 

CONTACT: 

J.J. Pellegrino, CFO, LeMaitre
781-425-1691
jjpellegrino@lemaitre.com

 

 
 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

CONDENSED CONSOLIDATED BALANCE SHEETS 

(amounts in thousands)

 

   

December 31, 2022

    

December 31, 2021

  
   

(unaudited)

          

Assets

                
                 

Current assets:

                

Cash and cash equivalents

   $ 19,134     $ 13,855  

Short-term marketable securities

     63,557       56,104  

Accounts receivable, net

     22,040       19,631  

Inventory and other deferred costs

     50,271       46,104  

Prepaid expenses and other current assets

     6,731       4,189  

Total current assets

     161,733       139,883  
                 

Property and equipment, net

     17,901       17,059  

Right-of-use leased assets

     15,634       15,071  

Goodwill

     65,945       65,945  

Other intangibles, net

     46,527       52,710  

Deferred tax assets

     1,745       1,566  

Other assets

     991       568  
                 

Total assets

   $ 310,476     $ 292,802  
                 
                 

Liabilities and stockholders' equity

                
                 

Current liabilities:

                

Accounts payable

   $ 2,903     $ 2,340  

Accrued expenses

     19,967       16,332  

Acquisition-related obligations

     573       1,271  

Lease liabilities - short-term

     1,886       1,870  

Total current liabilities

     25,329       21,813  
                 

Lease liabilities - long-term

     14,710       14,067  

Deferred tax liabilities

     69       70  

Other long-term liabilities

     2,167       2,701  

Total liabilities

     42,275       38,651  
                 

Stockholders' equity

                

Common stock

     237       235  

Additional paid-in capital

     189,268       181,630  

Retained earnings

     97,773       88,125  

Accumulated other comprehensive loss

     (6,031 )     (3,435 )

Treasury stock

     (13,046 )     (12,404 )

Total stockholders' equity

     268,201       254,151  
                 

Total liabilities and stockholders' equity

   $ 310,476     $ 292,802  

 

 
 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(amounts in thousands, except per share amounts)

(unaudited)

 

   

For the three months ended

    

For the year ended

  
   

December 31, 2022

    

December 31, 2021

    

December 31, 2022

    

December 31, 2021

  
                                 

Net sales

   $ 40,954     $ 39,503     $ 161,651     $ 154,424  

Cost of sales

     14,900       13,547       56,755       53,042  
                                 

Gross profit

     26,054       25,956       104,896       101,382  
                                 

Operating expenses:

                                

Sales and marketing

     8,600       7,445       32,921       27,655  

General and administrative

     6,933       6,753       28,745       25,501  

Research and development

     3,554       3,457       13,294       11,801  

Restructuring

     -       -       3,107       -  

Total operating expenses

     19,087       17,655       78,067       64,957  
                                 

Income from operations

     6,967       8,301       26,829       36,425  
                                 

Other income (expense), net

                                

Interest income

     447       141       986       197  

Interest expense

     -       (526 )     -       (2,219 )

Other income (loss), net

     384       (11 )     (325 )     (116 )
                                 

Income before income taxes

     7,798       7,905       27,490       34,287  
                                 

Provision for income taxes

     2,171       1,730       6,854       7,380  
                                 

Net income

   $ 5,627     $ 6,175     $ 20,636     $ 26,907  
                                 

Earnings per share of common stock

                                

Basic

   $ 0.26     $ 0.28     $ 0.94     $ 1.27  

Diluted

   $ 0.25     $ 0.28     $ 0.93     $ 1.25  
                                 

Weighted - average shares outstanding:

                                

Basic

     22,023       21,860       21,975       21,157  

Diluted

     22,238       22,138       22,171       21,475  
                                 
                                 

Cash dividends declared per common share

   $ 0.125     $ 0.110     $ 0.500     $ 0.440  

 

 
 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

SELECTED NET SALES INFORMATION

(amounts in thousands)

(unaudited)

 

   

For the three months ended

   

For the year ended

 
   

December 31, 2022

    

December 31, 2021

    

December 31, 2022

    

December 31, 2021

  
   

$

    

%

     $     %     $     %     $     %  

Net Sales by Geography

                                                                

Americas

   $ 27,415       67 %   $ 25,948       65 %   $ 109,439       68 %   $ 102,265       66 %

Europe, Middle East and Africa

     10,689       26 %     10,932       28 %     41,854       26 %     42,132       27 %

Asia Pacific

     2,850       7 %     2,623       7 %     10,358       6 %     10,027       7 %

Total Net Sales

   $ 40,954       100 %   $ 39,503       100 %   $ 161,651       100 %   $ 154,424       100 %

 

 
 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

 

Reconciliation between GAAP and Non-GAAP sales growth:

                        

For the three months ended December 31, 2022

                        

Net sales as reported

   $ 40,954                  

Impact of currency exchange rate fluctuations

     1,737                  

Adjusted net sales

           $ 42,691          
                         

For the three months ended December 31, 2021

                        

Net sales as reported

   $ 39,503                  

Adjusted net sales

           $ 39,503          
                         

Adjusted net sales increase for the three months ended December 31, 2022

           $ 3,188       8 %
                         
                         

APAC sales growth reconciliation between GAAP and Non-GAAP:

                        

For the three months ended December 31, 2022

                        

Net sales as reported

   $ 2,850                  

Impact of currency exchange rate fluctuations

     350                  

APAC adjusted net sales

           $ 3,200          
                         

For the three months ended December 31, 2021

                        

Net sales as reported

   $ 2,623                  

Adjusted net sales

           $ 2,623          
                         

APAC adjusted net sales increase for the three months ended December 31, 2022

     $ 577       22 %
                         
                         

EMEA sales growth reconciliation between GAAP and Non-GAAP:

                        

For the three months ended December 31, 2022

                        

Net sales as reported

   $ 10,689                  

Impact of currency exchange rate fluctuations

     1,215                  

EMEA adjusted net sales

           $ 11,904          
                         

For the three months ended December 31, 2021

                        

Net sales as reported

   $ 10,932                  

Adjusted net sales

           $ 10,932          
                         

EMEA adjusted net sales increase for the three months ended December 31, 2022

     $ 972       9 %
                         
                         

Americas sales growth reconciliation between GAAP and Non-GAAP:

                        

For the three months ended December 31, 2022

                        

Net sales as reported

   $ 27,415                  

Impact of currency exchange rate fluctuations

     172                  

Americas adjusted net sales

           $ 27,587          
                         

For the three months ended December 31, 2021

                        

Net sales as reported

   $ 25,948                  

Adjusted net sales

           $ 25,948          
                         

Americas adjusted net sales increase for the three months ended December 31, 2022

     $ 1,639       6 %

 

 
 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

 

Reconciliation between GAAP and Non-GAAP projected sales growth:

                        

For the three months ending March 31, 2023

                        

Net sales per guidance (midpoint)

   $ 43,849                  

Impact of currency exchange rate fluctuations

     1,049                  

Adjusted projected net sales

           $ 44,898          
                         

For the three months ended March 31, 2022

                        

Net sales as reported

   $ 39,561                  

Adjusted net sales

           $ 39,561          
                         

Adjusted projected net sales increase for the three months ending March 31, 2023

     $ 5,337       13 %
                         
                         

Reconciliation between GAAP and Non-GAAP projected sales growth:

                        

For the year ending December 31, 2023

                        

Net sales per guidance (midpoint)

   $ 176,349                  

Impact of currency exchange rate fluctuations

     320                  

Adjusted projected net sales

           $ 176,669          
                         

For the year ended December 31, 2022

                        

Net sales as reported

   $ 161,651                  

Adjusted net sales

           $ 161,651          
                         

Adjusted projected net sales increase for the year ending December 31, 2023

     $ 15,018       9 %
                         
                         

Reconciliation between GAAP and Non-GAAP projected operating income

                        

For the year ending December 31, 2023

                        

Operating income per guidance (midpoint)

   $ 31,950                  

Adjusted operating income

           $ 31,950          
                         

For the year ended December 31, 2022

                        

Operating income as reported

   $ 26,829                  

Impact of special charge

     3,107                  

Adjusted operating income

           $ 29,936          
                         

Adjusted projected operating income increase for the year ending December 31, 2023

     $ 2,014       7 %
                         
                         

Reconciliation between GAAP and Non-GAAP projected EPS

                        

For the year ending December 31, 2023

                        

EPS per guidance (midpoint)

   $ 1.16                  

Adjusted EPS

           $ 1.16          
                         

For the year ended December 31, 2022

                        

EPS as reported

   $ 0.93                  

Impact of special charge

     0.14                  

Adjusted EPS

           $ 1.07          
                         

Adjusted projected EPS increase for the year ending December 31, 2023

           $ 0.09       8 %

 

 
 

 

LEMAITRE VASCULAR, INC. (NASDAQ: LMAT)

NON-GAAP FINANCIAL MEASURES

(amounts in thousands)

(unaudited)

 

   

For the three months ended

    

For the year ended

  
   

December 31, 2022

    

December 31, 2021

    

December 31, 2022

    

December 31, 2021

  

Reconciliation between GAAP and Non-GAAP EBITDA

                                

Net income as reported

   $ 5,627     $ 6,175     $ 20,636     $ 26,907  

Interest (income) expense, net

     (447 )     385       (986 )     2,022  

Amortization and depreciation expense

     2,288       2,359       9,433       9,475  

Provision for income taxes

     2,171       1,730       6,854       7,380  
                                 

EBITDA

   $ 9,639     $ 10,649     $ 35,937     $ 45,784  
                                 

EBITDA percentage increase (decrease)

             -9 %             -22 %

 

 
 EX-101.SCH 3 lmat-20230223.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 lmat-20230223_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 lmat-20230223_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, File Number Entity, Incorporation, State or Country Code Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 lmat-20230223_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information
Feb. 23, 2023
Document Information [Line Items]  
Entity, Registrant Name LeMaitre Vascular, Inc.
Document, Type 8-K
Document, Period End Date Feb. 23, 2023
Entity, File Number 001-33092
Entity, Incorporation, State or Country Code DE
Entity, Tax Identification Number 04-2825458
Entity, Address, Address Line One 63 Second Avenue
Entity, Address, City or Town Burlington
Entity, Address, State or Province MA
Entity, Address, Postal Zip Code 01803
City Area Code 781
Local Phone Number 221-2266
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol LMAT
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001158895
XML 8 lmat20230223_8k_htm.xml IDEA: XBRL DOCUMENT 0001158895 2023-02-23 2023-02-23 false 0001158895 8-K 2023-02-23 LeMaitre Vascular, Inc. 001-33092 DE 04-2825458 63 Second Avenue Burlington MA 01803 781 221-2266 false false false false Common stock LMAT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.lmat.com/20230223/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports lmat20230223_8k.htm ex_479795.htm lmat-20230223.xsd lmat-20230223_def.xml lmat-20230223_lab.xml lmat-20230223_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lmat20230223_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "lmat-20230223_def.xml" ] }, "inline": { "local": [ "lmat20230223_8k.htm" ] }, "labelLink": { "local": [ "lmat-20230223_lab.xml" ] }, "presentationLink": { "local": [ "lmat-20230223_pre.xml" ] }, "schema": { "local": [ "lmat-20230223.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lmat", "nsuri": "http://www.lmat.com/20230223", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lmat20230223_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.lmat.com/20230223/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "lmat20230223_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.lmat.com/20230223/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001437749-23-004378-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-004378-xbrl.zip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end